Notable Analyst Rating Changes 02/23: (AMAT) (AKS) (YOKU) (HOC) Upgraded; (NFLX) (FRX) (MDT) (MRO) Downgraded
Up)
UPGRADES
Piper Jaffray upgraded Applied Materials (Nasdaq: AMAT) from Neutral to Overweight, with a price target increased from $12 to $22.
KeyBanc raises AK Steel (NYSE: AKS) from Hold to Buy, with a price target of $20. Click Here for more color.
Goldman Sachs upgrades Youku.com (NYSE: YOKU) from Neutral to Buy with a $40 price target. Click Here for more color.
Raymond James ups Holly Corp (NYSE: HOC) from Market Perform to Outperform.
For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades
DOWNGRADES
Needham & Company downgraded Netflix (Nasdaq: NFLX) from Hold to Underperform. Click here for more color.
Forest Laboratories (NYSE: FRX) lowered by two firms today:
Marathon Oil (NYSE: MRO) downgraded by two today:
Piper Jaffray upgraded Applied Materials (Nasdaq: AMAT) from Neutral to Overweight, with a price target increased from $12 to $22.
KeyBanc raises AK Steel (NYSE: AKS) from Hold to Buy, with a price target of $20. Click Here for more color.
Goldman Sachs upgrades Youku.com (NYSE: YOKU) from Neutral to Buy with a $40 price target. Click Here for more color.
Raymond James ups Holly Corp (NYSE: HOC) from Market Perform to Outperform.
For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades
DOWNGRADES
Needham & Company downgraded Netflix (Nasdaq: NFLX) from Hold to Underperform. Click here for more color.
Forest Laboratories (NYSE: FRX) lowered by two firms today:
- Citi from Buy to Hold; and
- Merriman Curhan Ford from Buy to Neutral.
Marathon Oil (NYSE: MRO) downgraded by two today:
- Howard Weil downgraded Marathon Oil (NYSE: MRO) from Focus Stock to Market Outperform, increasing their price target from $56 to $58.
For daily real-time Downgrades go to http://www.streetinsider.com/downgrades
NEW COVERAGE
Goldman Sachs initiates coverage on Qiagen NV (Nasdaq: QGEN) with a Sell rating and $18 price target.
Jefferies initiates Crown Holdings (NYSE: CCK) with a Buy rating and a $46 price target. Click Here for more color.
Goldman Sachs initiates coverage on Myriad Genetics (Nasdaq: MYGN) with a Sell and $17 price target. Click Here for more color.
Barclays initiates coverage on ZIOPHARM Oncology (NASDAQ: ZIOP) with a Overweight, and $9 price target.
For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage
Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Piper Jaffray, Citi, KeyBanc, Raymond James, Jefferies & Co, Needham & Company, Merriman Curhan Ford, Barclays, Notable Analyst Rating ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
